Chronic Limb-Threatening Ischemia (CLTI)
Advanced peripheral artery disease with critically reduced blood flow, non‑healing wounds, and rising limb‑loss risk.
When revascularization options are limited, patients need timely evaluation and specialized ischemia management.
Learn how CLTI progresses, why wounds fail to heal, and what clinical pathways exist when standard therapies are exhausted.
Chronic Limb-Threatening Ischemia:
What It Is and Why It Matters
Chronic limb-threatening ischemia (CLTI) is the most advanced stage of peripheral arterial disease (PAD), a condition where severely reduced blood flow to the legs and feet puts the limb itself at risk. When arteries become too narrowed or blocked to deliver enough oxygen to the tissues, the body can no longer compensate. Wounds stop healing, pain becomes constant, and without intervention, tissue begins to die.
CLTI is not just a circulation problem. It is a limb-threatening and life-threatening condition. People living with CLTI face a high risk of amputation, and the same vascular disease affecting their legs is almost always affecting their heart and brain as well.
Unlike earlier stages of PAD where pain only appears during walking or exertion, CLTI means the ischemia is present at rest. The tissue is under constant stress. Every day without adequate blood flow increases the risk of irreversible damage.
Understanding CLTI, what causes it, how it progresses, and what options exist, is the first step toward getting the right evaluation and the right care.
Symptoms and the Lived Experience of CLTI
CLTI doesn't announce itself all at once. For most people, it develops gradually, starting with leg pain during walking that slowly becomes pain at rest, then wounds that won't heal, then a constant, exhausting battle to preserve the limb. By the time a CLTI diagnosis is made, many patients have been managing worsening symptoms for months or years.
Living with CLTI is physically and emotionally exhausting. The fear of amputation is real and constant. Many patients describe feeling desperate, dismissed, or caught between specialists who have run out of options. Sleep is disrupted by pain. Mobility is lost. Independence shrinks. The emotional weight of watching a wound worsen despite doing everything right is something that doesn't show up in test results, but it defines daily life for CLTI patients and their families.
Why Chronic Limb-Threatening Ischemia Happens
CLTI develops when blood flow to the legs and feet becomes so severely reduced that tissues can no longer survive on the oxygen they receive. This is almost always the result of years of progressive vascular disease, not a single event. Understanding the underlying mechanisms helps patients make sense of how their condition developed and why it continues to progress.
Why Chronic Limb-Threatening Ischemia Happens
CLTI develops when blood flow to the legs and feet becomes so severely reduced that tissues can no longer survive on the oxygen they receive. This is almost always the result of years of progressive vascular disease, not a single event. Understanding the underlying mechanisms helps patients make sense of how their condition developed and why it continues to progress.
Advanced Atherosclerosis
Plaque made of cholesterol, calcium, and inflammatory cells builds up inside the arteries supplying the legs. Over time, vessels narrow and stiffen until blood flow drops below the threshold needed to keep tissue alive, even at rest.
Microvascular Dysfunction
In many CLTI patients, the small vessels responsible for delivering oxygen directly to tissue are also damaged. Even when larger arteries are treated, microvascular failure can prevent adequate perfusion from reaching the foot and toes.
Diabetes and Vascular Damage
Diabetes accelerates arterial disease, promotes nerve damage, and impairs the body's ability to fight infection and heal wounds. Diabetic patients are significantly more likely to develop CLTI and face higher rates of amputation when they do.
Endothelial Injury
The inner lining of blood vessels becomes damaged by high blood pressure, smoking, high cholesterol, and chronic inflammation. When the endothelium loses its ability to regulate blood flow, perfusion to the extremities deteriorates progressively.
Collateral Circulation Failure
The body attempts to compensate for blocked arteries by developing collateral vessels - natural bypass routes. In CLTI, this compensatory mechanism has failed. Collateral circulation is no longer sufficient to meet even the baseline oxygen demands of resting tissue.
A Systemic Vascular Pattern
The same disease process driving CLTI rarely stays confined to the legs. Atherosclerosis affecting the lower extremities is frequently accompanied by coronary artery disease, cardiovascular ischemia, and vascular dementia -- reflecting a body-wide breakdown in vascular health.
Types of Chronic Limb-Threatening Ischemia
CLTI is not a single presentation. It appears across a spectrum of severity, and understanding which form a patient has directly affects how it is evaluated, treated, and monitored. These categories often overlap; many patients present with more than one at the same time.
Types of Chronic Limb-Threatening Ischemia
CLTI is not a single presentation. It appears across a spectrum of severity, and understanding which form a patient has directly affects how it is evaluated, treated, and monitored. These categories often overlap; many patients present with more than one at the same time.
Ischemic Rest Pain
Pain that occurs without any physical activity, most commonly in the foot or toes. It typically worsens when the leg is elevated and improves slightly when dangled downward. Rest pain signals that blood flow is critically insufficient even at baseline metabolic demand. It is one of the earliest defining features of CLTI.
Ischemic Ulceration
Wounds or sores that develop on the feet, toes, or heels and fail to heal despite appropriate wound care. Ischemic ulcers form because tissue cannot repair itself without adequate oxygen. They are prone to infection, slow to respond to treatment, and can deteriorate rapidly without restored blood flow.
Tissue Loss and Gangrene
When perfusion drops below the threshold for tissue viability, tissue begins to die. Dry gangrene typically begins in the toes or forefoot and can progress if blood flow is not restored. This stage represents a surgical emergency in many cases and carries the highest risk of major amputation.
Microvascular CLTI
Some patients have critically impaired perfusion at the small vessel level even when larger arteries appear treatable or have already been treated. Microvascular CLTI is particularly common in diabetic patients and often explains why wounds fail to heal after successful revascularization.
No-Option CLTI
A subset of patients are not candidates for bypass surgery or endovascular intervention due to diffuse disease, prior failed procedures, vessel anatomy, or comorbidities that make surgery too risky. These patients face the highest risk of amputation and are often the most appropriate candidates for investigational evaluation.
A Systemic Pattern
CLTI rarely exists in isolation. The vascular disease driving limb ischemia is the same disease affecting the heart and brain. Patients with CLTI have significantly elevated rates of cardiovascular ischemia, heart attack, stroke, and vascular dementia -- making comprehensive vascular evaluation essential.
How Chronic Limb-Threatening Ischemia Is Diagnosed
Diagnosing CLTI requires confirming that blood flow is critically reduced and understanding the anatomy of the disease well enough to guide treatment decisions. Because CLTI exists on a spectrum and can involve both large and small vessel disease, diagnosis is rarely based on a single test. Clinicians assemble a picture from symptoms, physical findings, hemodynamic measurements, and imaging.
Clinical History and Symptom Review
The process begins with a detailed conversation about symptoms, their pattern, and how they have changed over time -- including rest pain, wound history, prior interventions, and how daily life has been affected. This context is essential for understanding severity and identifying patients who may no longer be candidates for standard revascularization.
Ankle-Brachial Index (ABI) and Toe Pressures
The ABI compares blood pressure in the ankle to the arm to quantify perfusion impairment. In patients with diabetes or noncompressible vessels, toe pressure measurements provide a more accurate picture of distal blood flow. Severely reduced values confirm critical ischemia.
Duplex Ultrasonography
Uses sound waves to evaluate blood flow patterns and identify the location and severity of arterial narrowing or blockage. Non-invasive, widely available, and often the first imaging step in CLTI evaluation.
CT or MR Angiography
Provides detailed anatomical mapping of arterial disease from the aorta to the foot. Essential for planning revascularization and identifying whether bypass or endovascular intervention is technically feasible.
Conventional Angiography
The gold standard for detailed anatomical assessment. Used when revascularization is being planned and precise visualization of vessel anatomy is required. Can be combined with intervention in the same procedure.
Why Some Patients Are Told There Are No Options
When imaging reveals diffuse multilevel disease, heavily calcified vessels, or anatomy that cannot be safely treated, patients may be told revascularization is no longer possible. This is not the end of evaluation -- it is the point where investigational research pathways become most relevant.
How Chronic Limb-Threatening Ischemia Progresses Over Time
CLTI does not develop overnight. It is the endpoint of a long progression of vascular disease that advances in stages -- often over years. Understanding this trajectory helps patients recognize where they are in the process, why symptoms are changing, and why timing matters when it comes to evaluation and intervention.
Stage 1: Peripheral Arterial Disease Without Symptoms
Arterial narrowing is present but the body is still compensating. Many patients have no symptoms at this stage, or attribute mild fatigue and leg heaviness to aging. PAD is often detected incidentally during routine cardiovascular evaluation. Risk factor management at this stage can significantly slow progression.
Stage 2: Intermittent Claudication
Blood flow is insufficient during exertion but adequate at rest. Patients experience cramping, aching, or fatigue in the calves, thighs, or buttocks during walking that resolves with rest. This is the stage most people recognize as PAD, but it is still well before CLTI.
Stage 3: Ischemic Rest Pain
Blood flow can no longer meet even baseline tissue demands. Pain occurs at rest, typically in the foot or toes, and is often worst at night. Patients begin dangling their foot off the bed for relief. This marks the transition into CLTI territory and requires urgent vascular evaluation.
Stage 4: Tissue Loss and Non-Healing Wounds
Oxygen deprivation has progressed to the point where the skin and underlying tissue can no longer repair themselves. Ulcers develop on pressure points, toes, heels, forefoot, and fail to respond to wound care. Infection risk is high. Without restored blood flow, wounds expand rather than heal.
Stage 5: Gangrene and Limb Threat
Tissue death is occurring. Blackening or darkening of the toes or forefoot indicates irreversible damage. At this stage the risk of major amputation is highest and intervention, surgical, endovascular, or investigational, becomes urgent. Patients who reach this stage without revascularization options are among the most underserved in vascular medicine.
Current Treatment for Chronic Limb-Threatening Ischemia
Treatment for CLTI focuses on restoring blood flow to the limb, preventing infection, preserving tissue, and reducing the systemic cardiovascular risk that almost always accompanies advanced vascular disease. The right approach depends on the anatomy of the disease, the condition of the vessels, and the overall health of the patient.
Risk Factor Management
Controlling blood pressure, cholesterol, blood sugar, and smoking is foundational at every stage. These systemic factors drive ongoing plaque progression and vascular damage, managing them aggressively slows disease and improves outcomes after intervention.
Medications
Antiplatelet therapy, statins, and medications that improve circulation are standard for all CLTI patients. In diabetic patients, optimizing glycemic control is critical. Medications manage systemic risk but cannot restore blood flow to critically ischemic tissue on their own.
Wound Care
Specialized wound management is essential for patients with ischemic ulcers. This includes offloading pressure from affected areas, infection control, and advanced wound care techniques. Wound healing is severely limited without restored perfusion, wound care alone is rarely sufficient in true CLTI.
Endovascular Intervention
Minimally invasive procedures, including balloon angioplasty and stenting, can open blocked or narrowed arteries and restore blood flow. Most effective when disease is localized and vessels are suitable for catheter-based treatment. Often the first revascularization option considered.
Surgical Bypass
For patients with complex, multilevel, or diffuse disease not suitable for endovascular treatment, bypass surgery creates a new pathway for blood to reach the foot using a vein or synthetic graft. Requires adequate inflow and a suitable target vessel below the blockage.
Multidisciplinary Care
CLTI management requires coordinated care across vascular surgery, interventional radiology, wound care, endocrinology, and cardiology. No single specialist owns this condition, the best outcomes come from teams that treat the whole patient, not just the affected limb.
When Patients Explore Investigational Options
For some CLTI patients, revascularization is no longer possible. The arteries are too diseased, too calcified, or too diffuse to treat with stents or bypass. Prior surgeries have used available vessel segments. The risks of further intervention outweigh the potential benefit. When a vascular specialist delivers this news, it can feel like a door closing permanently.
It isn't.
Investigational clinical research exists specifically for patients in this position. It does not replace standard medical care and it does not promise specific outcomes. But it offers a structured, science-driven pathway for patients who still have symptoms, still have a limb worth fighting for, and still want to understand whether research participation may be appropriate for their situation.
Why Patients Begin Looking Further
People with CLTI may explore investigational options when they experience non-healing wounds that have failed to respond to weeks or months of wound care; rest pain that disrupts sleep and daily function despite optimized medical therapy; a "no-option" designation after evaluation by one or more vascular specialists; progressive tissue loss with amputation being discussed as the next step; or a strong desire to exhaust every possible avenue before accepting limb loss.
This is one of the most emotionally difficult positions a patient can be in. The fear of amputation is not abstract - it is immediate, practical, and life-altering. Many patients describe feeling abandoned by the medical system at exactly the moment they need it most. Seeking investigational evaluation is not desperation. It is informed advocacy for your own care.
What Investigational Evaluation Involves
Investigational evaluation is a structured clinical review under regulated research protocols. It begins with a thorough assessment of medical history, prior imaging, wound status, and current symptoms to determine whether a patient meets eligibility criteria for a research study.
Hemostemix evaluates certain no-option CLTI patients under investigational protocols involving ACP-01 -- an autologous cell product derived from a patient's own blood being studied for its potential to support blood vessel growth and improve tissue perfusion in critically ischemic limbs.
Hemostemix's Investigational Approach
Hemostemix evaluates certain patients with chronic limb-threatening ischemia under regulated research protocols studying whether ACP-01, an autologous angiogenic cell product, may support blood flow in critically ischemic limbs. This is investigational. It has not been approved by the FDA, does not replace standard medical care, and requires meeting specific eligibility criteria.
Hemostemix's Investigational Approach
Hemostemix evaluates certain patients with chronic limb-threatening ischemia under regulated research protocols studying whether ACP-01, an autologous angiogenic cell product, may support blood flow in critically ischemic limbs. This is investigational. It has not been approved by the FDA, does not replace standard medical care, and requires meeting specific eligibility criteria.
What ACP-01 Is
ACP-01 consists of angiogenic cell precursors derived from a patient's own blood, prepared in a controlled laboratory environment. Because the cells are autologous, there is no risk of immune rejection. They are being studied for their potential to support vascular repair in ischemic tissue.
How It Works
The process involves a standard blood draw, laboratory isolation and preparation of the angiogenic precursor cells, and reinjection into the area of ischemia using catheter-based techniques. No general anesthesia is required and most patients return to normal activities shortly after.
What It Is and What It Isn't
ACP-01 is not an approved treatment, not a replacement for ongoing medical care, and does not guarantee specific outcomes. It is a structured, science-driven pathway for patients who have exhausted standard options and want to understand whether research participation may be appropriate for their clinical profile.
Request A Clinical Research Consultation
Request A Clinical Research Consultation
If you have been diagnosed with an advanced vascular or ischemic condition and are exploring investigational clinical research options, you may request a consultation to determine whether further review is appropriate.
Frequently Asked Questions
What is the difference between PAD and CLTI?
Peripheral arterial disease (PAD) refers broadly to arterial narrowing in the legs and feet. CLTI is the most advanced stage of PAD -- defined by critically reduced blood flow that causes rest pain, non-healing wounds, or tissue loss. Not everyone with PAD develops CLTI, but CLTI always involves underlying PAD.
What are the warning signs that PAD has progressed to CLTI?
Key warning signs include pain in the foot or toes at rest -- especially at night -- wounds or sores that fail to heal despite treatment, skin that appears shiny, thin, or discolored, and toes that feel cold or look pale or darkened. If any of these are present, urgent vascular evaluation is needed.
Is CLTI life-threatening?
Yes. CLTI is associated with high rates of major amputation and elevated cardiovascular mortality. The same vascular disease affecting the legs is almost always present in the heart and brain. Patients with CLTI face significantly increased risk of heart attack, stroke, and death within one to two years of diagnosis without appropriate management.
Can CLTI be reversed?
In some cases, restoring blood flow through endovascular intervention or bypass surgery can significantly improve perfusion, allow wounds to heal, and prevent amputation. However, not all patients are candidates for revascularization, and outcomes depend heavily on disease severity, timing, and overall health.
What happens if CLTI is left untreated?
Without restored blood flow, tissue continues to die. Infection can develop in non-healing wounds and spread to bone. Progressive gangrene may make major amputation unavoidable. Early evaluation and intervention are critical to preserving the limb.
What happens if CLTI is left untreated?
Without restored blood flow, tissue continues to die. Infection can develop in non-healing wounds and spread to bone. Progressive gangrene may make major amputation unavoidable. Early evaluation and intervention are critical to preserving the limb.
What does "no-option" CLTI mean?
No-option CLTI describes patients who are not candidates for bypass surgery or endovascular procedures due to diffuse disease, vessel anatomy, prior failed interventions, or surgical risk. These patients face the highest amputation risk and are often the most appropriate candidates for investigational research evaluation.
Is ACP-01 approved for CLTI?
No. ACP-01 is investigational and has not been approved by the U.S. Food and Drug Administration. It is being evaluated in structured clinical research programs for patients with ischemic conditions including chronic limb-threatening ischemia.
How do I find out if I qualify for investigational evaluation?
Contact Hemostemix directly to request a clinical consultation. Our team will review your medical history, prior imaging, and current symptoms to determine whether further evaluation is appropriate for your situation.
Disclaimer